Current management of cancer-associated anorexia and weight loss

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Loss of appetite and weight predict a poor prognosis for cancer patients. Although caloric supplementation might benefit subgroups of patients - specifically, perioperative, severely malnourished cancer patients, stem cell and bone marrow transplant patients, and head and neck cancer patients - its use remains controversial and is not recommended for the majority of patients with cancer-associated weight loss. Most patients with advanced cancer, anorexia, and/or weight loss do not appear to benefit from nutritional supplementation. Instead, discussions with patients and families about realistic eating goals and, at times, pharmacologic interventions with progestational agents or corticosteroids - both of which are aimed at palliating anorexia - provide clinical benefit. Other pharmacologic interventions such as eicosapentaenoic acid, thalidomide (Thalomid), adenosine triphosphate, and nonsteroidal anti-inflammatory agents focus on the fact that cancer-associated weight loss is an entity distinct from simple starvation. These interventions promise to replenish lean tissue but require further investigation before they can be recommended as standard clinical practice.

Original languageEnglish (US)
Pages (from-to)497-508
Number of pages12
JournalOncology
Volume15
Issue number4
StatePublished - 2001

Fingerprint

Anorexia
Weight Loss
Neoplasms
Thalidomide
Eicosapentaenoic Acid
Neoplastic Stem Cells
Non-Steroidal Anti-Inflammatory Agents
Appetite
Progestins
Head and Neck Neoplasms
Starvation
Adrenal Cortex Hormones
Eating
Adenosine Triphosphate
Bone Marrow
Transplants

ASJC Scopus subject areas

  • Oncology

Cite this

Current management of cancer-associated anorexia and weight loss. / Jatoi, Aminah; Loprinzi, Charles Lawrence.

In: Oncology, Vol. 15, No. 4, 2001, p. 497-508.

Research output: Contribution to journalArticle

@article{f0f88343269c4f28847b7ec22347e829,
title = "Current management of cancer-associated anorexia and weight loss",
abstract = "Loss of appetite and weight predict a poor prognosis for cancer patients. Although caloric supplementation might benefit subgroups of patients - specifically, perioperative, severely malnourished cancer patients, stem cell and bone marrow transplant patients, and head and neck cancer patients - its use remains controversial and is not recommended for the majority of patients with cancer-associated weight loss. Most patients with advanced cancer, anorexia, and/or weight loss do not appear to benefit from nutritional supplementation. Instead, discussions with patients and families about realistic eating goals and, at times, pharmacologic interventions with progestational agents or corticosteroids - both of which are aimed at palliating anorexia - provide clinical benefit. Other pharmacologic interventions such as eicosapentaenoic acid, thalidomide (Thalomid), adenosine triphosphate, and nonsteroidal anti-inflammatory agents focus on the fact that cancer-associated weight loss is an entity distinct from simple starvation. These interventions promise to replenish lean tissue but require further investigation before they can be recommended as standard clinical practice.",
author = "Aminah Jatoi and Loprinzi, {Charles Lawrence}",
year = "2001",
language = "English (US)",
volume = "15",
pages = "497--508",
journal = "Oncology",
issn = "0030-2414",
publisher = "UBM Medica Healthcare Publications",
number = "4",

}

TY - JOUR

T1 - Current management of cancer-associated anorexia and weight loss

AU - Jatoi, Aminah

AU - Loprinzi, Charles Lawrence

PY - 2001

Y1 - 2001

N2 - Loss of appetite and weight predict a poor prognosis for cancer patients. Although caloric supplementation might benefit subgroups of patients - specifically, perioperative, severely malnourished cancer patients, stem cell and bone marrow transplant patients, and head and neck cancer patients - its use remains controversial and is not recommended for the majority of patients with cancer-associated weight loss. Most patients with advanced cancer, anorexia, and/or weight loss do not appear to benefit from nutritional supplementation. Instead, discussions with patients and families about realistic eating goals and, at times, pharmacologic interventions with progestational agents or corticosteroids - both of which are aimed at palliating anorexia - provide clinical benefit. Other pharmacologic interventions such as eicosapentaenoic acid, thalidomide (Thalomid), adenosine triphosphate, and nonsteroidal anti-inflammatory agents focus on the fact that cancer-associated weight loss is an entity distinct from simple starvation. These interventions promise to replenish lean tissue but require further investigation before they can be recommended as standard clinical practice.

AB - Loss of appetite and weight predict a poor prognosis for cancer patients. Although caloric supplementation might benefit subgroups of patients - specifically, perioperative, severely malnourished cancer patients, stem cell and bone marrow transplant patients, and head and neck cancer patients - its use remains controversial and is not recommended for the majority of patients with cancer-associated weight loss. Most patients with advanced cancer, anorexia, and/or weight loss do not appear to benefit from nutritional supplementation. Instead, discussions with patients and families about realistic eating goals and, at times, pharmacologic interventions with progestational agents or corticosteroids - both of which are aimed at palliating anorexia - provide clinical benefit. Other pharmacologic interventions such as eicosapentaenoic acid, thalidomide (Thalomid), adenosine triphosphate, and nonsteroidal anti-inflammatory agents focus on the fact that cancer-associated weight loss is an entity distinct from simple starvation. These interventions promise to replenish lean tissue but require further investigation before they can be recommended as standard clinical practice.

UR - http://www.scopus.com/inward/record.url?scp=0035319845&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035319845&partnerID=8YFLogxK

M3 - Article

C2 - 11346935

AN - SCOPUS:0035319845

VL - 15

SP - 497

EP - 508

JO - Oncology

JF - Oncology

SN - 0030-2414

IS - 4

ER -